Cargando…

Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome

PURPOSE: Literature regarding endogenous Cushing syndrome (CS) largely focuses on the challenges of diagnosis, subtyping, and treatment. The enigmatic phenomenon of glucocorticoid withdrawal syndrome (GWS), due to rapid reduction in cortisol exposure following treatment of CS, is less commonly discu...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Xin, Findling, James W., Auchus, Richard J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170649/ https://www.ncbi.nlm.nih.gov/pubmed/35471718 http://dx.doi.org/10.1007/s11102-022-01218-y

Ejemplares similares

SUN-451 A Randomized-Withdrawal, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Selective Glucocorticoid Receptor Antagonist, Relacorilant, in Patients with Cushing Syndrome (GRACE Study)
por: Auchus, Richard, et al.
Publicado: (2019)

Levoketoconazole treatment in endogenous Cushing’s syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes
por: Fleseriu, Maria, et al.
Publicado: (2022)

Recognition of Nonneoplastic Hypercortisolism in the Evaluation of Patients With Cushing Syndrome
por: Findling, James W, et al.
Publicado: (2023)

COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess
por: Pivonello, Rosario, et al.
Publicado: (2020)

Levoketoconazole in the treatment of patients with endogenous Cushing’s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS)
por: Pivonello, Rosario, et al.
Publicado: (2022)

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome
por: Moraitis, Andreas G., et al.
Publicado: (2016)

MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study
por: Zacharieva, Sabina Z, et al.
Publicado: (2020)

Invasive fungal infections in endogenous Cushing's syndrome
por: Scheffel, Rafael Selbach, et al.
Publicado: (2010)

Cushing’s syndrome with no clinical stigmata – a variant of glucocorticoid resistance syndrome
por: Gossain, Ved V., et al.
Publicado: (2018)

Central serous chorioretinopathy in active endogenous Cushing’s syndrome
por: Brinks, Joost, et al.
Publicado: (2021)

Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study
por: Zacharieva, Sabina, et al.
Publicado: (2021)

OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3)
por: Biller, Beverly MK, et al.
Publicado: (2019)

Alcohol-induced Cushing syndrome: report of eight cases and review of the literature
por: Surani, Asif, et al.
Publicado: (2023)

SUN-387 ACTH-Independent Cushing Syndrome from Pregnancy-Induced Micronodular Hyperplasia
por: Affinati, Alison, et al.
Publicado: (2019)

Co-Occurrence of Exogenous and Endogenous Cushing's Syndromes—Dilemma in Diagnosis
por: Tong, Chin Voon, et al.
Publicado: (2019)

Incidence of Venous Thromboembolic Events in Patients With Endogenous Cushing Syndrome
por: Subbu, Karthik, et al.
Publicado: (2021)

The Effect of Endogenous Cushing Syndrome on All-cause and Cause-specific Mortality
por: Limumpornpetch, Padiporn, et al.
Publicado: (2022)

Improvement in cognitive impairment following the successful treatment of endogenous Cushing’s syndrome-a case report and literature review
por: Brzozowska, Malgorzata Monika, et al.
Publicado: (2019)

Glucocorticoid Regulation of Food-Choice Behavior in Humans: Evidence from Cushing's Syndrome
por: Moeller, Scott J., et al.
Publicado: (2016)

Continuous Etomidate Infusion for the Management of Severe Cushing Syndrome: Validation of a Standard Protocol
por: Carroll, Ty B, et al.
Publicado: (2018)

Comparison of hydrocortisone and prednisone in the glucocorticoid replacement therapy post-adrenalectomy of Cushing's Syndrome
por: Tang, Kunlong, et al.
Publicado: (2017)

Intraocular pressure and its correlation with midnight plasma cortisol level in Cushing's disease and other endogenous Cushing's syndrome
por: Mishra, Priyadarshini, et al.
Publicado: (2017)

Choroidal and Retinal Abnormalities by Optical Coherence Tomography in Endogenous Cushing’s Syndrome
por: Abalem, Maria Fernanda, et al.
Publicado: (2016)

Decreased Trabecular Bone Score in Patients With Active Endogenous Cushing’s Syndrome
por: Stachowska, Barbara, et al.
Publicado: (2021)

Clinical Characteristics of Endogenous Cushing's Syndrome at a Medical Center in Southern Taiwan
por: Tung, Shih-Chen, et al.
Publicado: (2013)

Apoptosis Evaluation in Circulating CD34+-Enriched Hematopoietic Stem and Progenitor Cells in Patients with Abnormally Increased Production of Endogenous Glucocorticoids in Course of Cushing’s Syndrome
por: Kawa, Miłosz P., et al.
Publicado: (2022)

Decreased Lymphocytes and Increased Risk for Infection are Common in Endogenous Pediatric Cushing Syndrome
por: Tatsi, Christina, et al.
Publicado: (2017)

Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing’s syndrome: cohort study
por: Fardet, Laurence, et al.
Publicado: (2012)

Disturbed bone marrow adiposity in patients with Cushing’s syndrome and glucocorticoid- and postmenopausal- induced osteoporosis
por: Sørensen, Nina N., et al.
Publicado: (2023)

Prospective Evaluation of Late-Night Salivary Cortisol and Cortisone by EIA and LC-MS/MS in Suspected Cushing Syndrome
por: Kannankeril, Joshua, et al.
Publicado: (2020)

Validity of discharge ICD-10 codes in detecting the etiologies of endogenous Cushing’s syndrome
por: Zhou, Jingya, et al.
Publicado: (2019)

Topical glucocorticoid application causing iatrogenic Cushing’s syndrome followed by secondary adrenal insufficiency in infants: two case reports
por: Matejek, Nicola, et al.
Publicado: (2022)

THU035 Impact Of Surgery Or Medical Treatment With The Selective Glucocorticoid Receptor Modulator Relacorilant On Hypercoagulopathy In Patients With Cushing Syndrome
por: Simeoli, Chiara, et al.
Publicado: (2023)

Glucocorticoid receptor polymorphisms modulate cardiometabolic risk factors in patients in long-term remission of Cushing’s syndrome
por: Roerink, Sean H. P. P., et al.
Publicado: (2016)

Clinical Characteristics and Treatment Outcomes in Endogenous Cushing's Syndrome: A 15-Year Experience from Thailand
por: Parksook, Wasita Warachit, et al.
Publicado: (2020)

Adrenal Insufficiency under Standard Dosage of Glucocorticoid Replacement after Unilateral Adrenalectomy for Cushing's Syndrome
por: Fujii, Kentaro, et al.
Publicado: (2016)

Iatrogenic Cushing’s Syndrome: The Result of Cobicistat and Glucocorticoid Interaction in an HIV Patient After Bariatric Surgery
por: Benido Silva, Vânia, et al.
Publicado: (2023)

Cushing's Syndrome and Treatment-Resistant Depression
por: Shukla, Lekhansh
Publicado: (2017)

Mifepristone for Treatment of Metabolic Syndrome: Beyond Cushing’s Syndrome
por: Díaz-Castro, Francisco, et al.
Publicado: (2020)

Different Potent Glucocorticoids, Different Routes of Exposure but the Same Result: Iatrogenic Cushing’s Syndrome and Adrenal Insufficiency
por: Güven, Ayla
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qlcgjs3r6oofc4otec1np40cu4